Darzalex Excites As Potential Grows In Multiple Myeloma
Executive Summary
Positive top-line results from the MAIA study of daratumumab as a front-line treatment for multiple myeloma highlights the future sales growth potential of Genmab/J&J's CD38-targeted antibody, which could become the market leader in the sector in the next five years.
You may also be interested in...
Working Toward A Cure: Janssen’s Multiple Myeloma Strategy
Janssen’s Mark Wildgust explained how the Johnson & Johnson subsidiary is pushing forward with novel therapeutics and combination regimens with the goal of eliminating myeloma in the first line.
EU Approvals: J&J's Darzalex Steps Ahead With New Indication
The European Commission has approved Johnson & Johnson’s/Genmab’s CD38-targeted MAb, daratumumab, and Merck & Co’s checkpoint inhibitor, pembrolizumab, in two first-line additional indications, in multiple myeloma and head and neck cancer, respectively.
Sanofi Myeloma Drug Shines But Darzalex Dominates Still
While data on Sanofi's anti-CD38 antibody isatuximab impressed at ASCO, analysts believe that the position of Johnson & Johnson's Darzalex in the multiple myeloma space is unlikely to be threatened.